|
US4271068A
(en)
|
1968-05-10 |
1981-06-02 |
Ciba-Geigy Corporation |
Process for the manufacture of cystine-containing peptides
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4033940A
(en)
|
1975-11-12 |
1977-07-05 |
Armour Pharmaceutical Company |
Cyclization of peptides
|
|
US4216141A
(en)
|
1978-07-19 |
1980-08-05 |
The Salk Institute For Biological Studies |
Method for cyclization of peptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
NZ199722A
(en)
|
1981-02-25 |
1985-12-13 |
Genentech Inc |
Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5371109A
(en)
|
1986-07-01 |
1994-12-06 |
Drilletten Ab |
Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
AU638762B2
(en)
|
1989-10-05 |
1993-07-08 |
Optein Inc |
Cell-free synthesis and isolation of novel genes and polypeptides
|
|
US5585353A
(en)
|
1990-02-02 |
1996-12-17 |
The Rockefeller University |
Antibiotic peptides containing D-amino acids
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5766897A
(en)
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US5843701A
(en)
|
1990-08-02 |
1998-12-01 |
Nexstar Pharmaceticals, Inc. |
Systematic polypeptide evolution by reverse translation
|
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
AU684510B2
(en)
|
1993-05-28 |
1997-12-18 |
Chiron Corporation |
Method for selection of biologically active peptide sequences
|
|
PT710243E
(pt)
|
1993-06-29 |
2000-11-30 |
Ferring Bv |
Sintese melhorada de peptidos ciclicos.
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US5834318A
(en)
|
1995-05-10 |
1998-11-10 |
Bayer Corporation |
Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
|
|
US5912014A
(en)
|
1996-03-15 |
1999-06-15 |
Unigene Laboratories, Inc. |
Oral salmon calcitonin pharmaceutical products
|
|
US6720472B2
(en)
|
1996-07-12 |
2004-04-13 |
University Of Medicine And Dentistry Of New Jersey |
HMGI proteins in cancer and obesity
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DE69730157T2
(de)
|
1996-10-17 |
2005-07-28 |
Mitsubishi Chemical Corp. |
Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen
|
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
|
US5922680A
(en)
|
1996-10-23 |
1999-07-13 |
Ferring, B.V. |
Stabilized composition for oral administration of peptides
|
|
ATE332368T1
(de)
|
1997-01-21 |
2006-07-15 |
Gen Hospital Corp |
Selektion von proteinen mittels rns-protein fusionen
|
|
US6261804B1
(en)
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
EP0896001A1
(en)
|
1997-08-08 |
1999-02-10 |
Daicel Chemical Industries, Ltd. |
Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
|
|
US6429301B1
(en)
|
1998-04-17 |
2002-08-06 |
Whitehead Institute For Biomedical Research |
Use of a ribozyme to join nucleic acids and peptides
|
|
IL140930A0
(en)
|
1998-08-07 |
2002-02-10 |
Emisphere Tech Inc |
Compounds and compositions for delivering active agents
|
|
AU1705100A
(en)
|
1998-10-09 |
2000-05-01 |
Musc Foundation For Research Development |
Blocking factor b to treat complement-mediated immune disease
|
|
US6962781B1
(en)
|
2000-05-19 |
2005-11-08 |
Proteonova, Inc. |
In vitro evolution of nucleic acids and encoded polypeptide
|
|
US7244701B2
(en)
|
2000-06-16 |
2007-07-17 |
Zealand Phama A/S |
Diuretic peptide conjugate
|
|
EP2266606B1
(en)
|
2003-05-15 |
2014-09-10 |
Genentech, Inc. |
Methods and compositions for the prevention and treatment of sepsis
|
|
CA2579635A1
(en)
|
2003-09-10 |
2005-03-17 |
Baxter International Inc. |
Peptides that inhibit complement activation
|
|
JP4994039B2
(ja)
|
2003-11-26 |
2012-08-08 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
脂溶性または疎水性化合物の送達に有用なミセル系
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
WO2006066258A2
(en)
|
2004-12-17 |
2006-06-22 |
Neose Technologies, Inc. |
Lipoconjugation of peptides
|
|
WO2006078161A1
(en)
|
2005-01-24 |
2006-07-27 |
Pepscan Systems B.V. |
Binding compounds, immunogenic compounds and peptidomimetics
|
|
CA2610502A1
(en)
|
2005-03-29 |
2006-10-05 |
Cardax Pharmaceuticals, Inc. |
Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
|
|
WO2006128006A1
(en)
|
2005-05-26 |
2006-11-30 |
The Regents Of The University Of Colorado |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
EP1888031B1
(en)
|
2005-06-06 |
2013-01-23 |
Camurus Ab |
Glp-1 analogue formulations
|
|
SG10201804008UA
(en)
|
2005-11-04 |
2018-06-28 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
US20090220508A1
(en)
*
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
EP1876183A1
(en)
|
2006-07-04 |
2008-01-09 |
Technische Universität München |
Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
|
|
EP2073898A1
(en)
|
2006-10-10 |
2009-07-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Complement inhibition for improved nerve regeneration
|
|
US7736860B2
(en)
|
2006-11-09 |
2010-06-15 |
Univeristy Of Massachusetts |
Methods of identifying compounds for the treatment of sterile inflammation
|
|
AU2008228247A1
(en)
|
2007-03-22 |
2008-09-25 |
Novartis Ag |
C5 antigens and uses thereof
|
|
US20100015139A1
(en)
|
2008-07-10 |
2010-01-21 |
Rekha Bansal |
METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
|
|
CA2680833A1
(en)
|
2007-04-30 |
2008-11-13 |
Alcon Research, Ltd. |
Treatment of age-related macular degeneration using inhibitors of complement factor d
|
|
RU2473563C2
(ru)
|
2007-06-07 |
2013-01-27 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
|
|
US20110142837A1
(en)
|
2007-07-20 |
2011-06-16 |
Trustees Of The University Of Pennsylvania |
Method Of Treating Acute Respiratory Distress Syndrome
|
|
BRPI0817524A2
(pt)
|
2007-10-02 |
2017-05-02 |
Potentia Pharmaceuticals Inc |
liberação prolongada de análogos de compstatina provenientes de géis
|
|
WO2009067191A2
(en)
|
2007-11-16 |
2009-05-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of hepatitis c virus (hcv) infection
|
|
US20110190221A1
(en)
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
EP2324048A2
(en)
|
2008-07-30 |
2011-05-25 |
Cosmix Therapeutics Llc |
Peptide therapeutics that bind vegf and methods of use thereof
|
|
US20110172126A1
(en)
|
2008-09-03 |
2011-07-14 |
Xenome Ltd |
Libraries of peptide conjugates and methods for making them
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
AU2009230735B1
(en)
|
2009-01-08 |
2010-01-21 |
Shane Ramodien |
Electronic equipment housing
|
|
DK2488203T3
(en)
|
2009-10-16 |
2017-03-13 |
Omeros Corp |
METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
CA2795311A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
US9358266B2
(en)
|
2010-02-25 |
2016-06-07 |
The Trustees Of The University Of Pennsylvania |
Treatment of sepsis using complement inhibitors
|
|
EP2563359A1
(en)
|
2010-04-30 |
2013-03-06 |
Allergan, Inc. |
Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
MX2013011263A
(es)
*
|
2011-03-29 |
2014-03-27 |
Abbvie Inc |
Despliegue de cubierta mejorado en dispositivos de inyeccion automaticos.
|
|
BR112013025917A2
(pt)
|
2011-04-08 |
2016-12-20 |
Omeros Corp |
uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
|
|
EP2704744B1
(en)
*
|
2011-05-05 |
2019-04-24 |
Wellstat ImmunoTherapeutics, LLC |
Complement factor b analogs and their uses
|
|
WO2012162215A1
(en)
|
2011-05-20 |
2012-11-29 |
The Trustees Of The University Of Pennsylvania |
Promotion of fracture healing using complement inhibitors
|
|
WO2012174055A1
(en)
|
2011-06-13 |
2012-12-20 |
The Trustees Of The University Of Pennsylvania |
Wound healing using complement inhibitors
|
|
CN102321170B
(zh)
|
2011-09-14 |
2013-11-13 |
深圳翰宇药业股份有限公司 |
利拉鲁肽变构体及其缀合物
|
|
US20140296147A1
(en)
|
2011-10-06 |
2014-10-02 |
The Medicines Company |
Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
|
|
EP3511339B1
(en)
|
2012-02-20 |
2025-04-09 |
IPC Research, LLC |
Polypeptides binding to human complement c5
|
|
US20130246083A1
(en)
|
2012-03-16 |
2013-09-19 |
Alexion Pharmaceuticals, Inc. |
Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
|
|
WO2013172954A1
(en)
*
|
2012-05-17 |
2013-11-21 |
Ra Pharmaceuticals, Inc |
Peptide and peptidomimetic inhibitors
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
US20130345257A1
(en)
|
2012-06-26 |
2013-12-26 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
WO2014078622A1
(en)
|
2012-11-15 |
2014-05-22 |
The Brigham And Women's Hospital, Inc. |
Method and system for diagnosing and treating preeclampsia
|
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
|
US20140234275A1
(en)
|
2013-02-15 |
2014-08-21 |
Jason Williams |
Method for treating als via the increased production of factor h
|
|
US20150057342A1
(en)
|
2013-08-21 |
2015-02-26 |
Cannabics Pharmaceuticals Inc |
Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
|
|
CN104231085B
(zh)
*
|
2013-09-05 |
2017-03-15 |
复旦大学附属肿瘤医院 |
靶向特异性补体系统抑制剂、其制备方法及应用
|
|
CA2940319A1
(en)
|
2014-03-20 |
2015-09-24 |
Inflarx Gmbh |
Inhibitors of c5a for the treatment of viral pneumonia
|
|
EP3973994A1
(en)
*
|
2014-06-12 |
2022-03-30 |
RA Pharmaceuticals, Inc. |
Modulation of complement activity
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
EP3142656B1
(en)
|
2015-01-21 |
2018-10-17 |
Pacira Pharmaceuticals, Inc. |
Multivesicular liposome formulations of tranexamic acid
|
|
US9937222B2
(en)
*
|
2015-01-28 |
2018-04-10 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
RU2733720C2
(ru)
|
2015-12-16 |
2020-10-06 |
Ра Фармасьютикалз, Инк. |
Модуляторы активности комплемента
|
|
KR20190093196A
(ko)
|
2016-12-07 |
2019-08-08 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절인자
|
|
TWI826364B
(zh)
|
2017-04-03 |
2023-12-21 |
德商因夫萊亞斯有限公司 |
活性抑制劑於發炎性疾病之治療
|
|
EP3682016A4
(en)
|
2017-09-11 |
2021-06-02 |
RA Pharmaceuticals, Inc. |
FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
|
|
CN111683672A
(zh)
|
2017-12-04 |
2020-09-18 |
Ra制药公司 |
补体活性调节剂
|
|
TW202100179A
(zh)
|
2019-03-08 |
2021-01-01 |
美商Ｒａ製藥公司 |
補體活性之調節劑
|
|
SG11202109837SA
(en)
|
2019-04-24 |
2021-10-28 |
Ra Pharmaceuticals Inc |
Compositions and methods for modulating complement activity
|